The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000665336
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
8/05/2026
Date registered
Help: Date registered
4/06/2026
Date last updated
Help: Date last updated
28/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
4/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Brain stimulation to target sleep and cognition in obstructive sleep apnea
Scientific title
Neuromodulation to target slow oscillations during sleep and cognition in adults with obstructive sleep apnea: A randomised controlled trial
Additional trial identifiers [1] 317232 0
nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Obstructive Sleep Apnoea 341845 0
Condition category
Condition code
Respiratory 337907 337907 0 0
Sleep apnoea

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The overarching aim of this study is to evaluate and compare the effects of high-definition slow-oscillatory transcranial direct current stimulation (so-tDCS), applied to frontal and parietal regions, on slow oscillations during sleep and cognition in middle to late aged adults with obstructive sleep apnoea (OSA). We will recruit 24 participants. Participants will attend three overnight visits at the Woolcock Institute of Medical Research where they will receive either the active frontal (Arm 1), active parietal (Arm 2) or sham (Arm 3) stimulation condition in random order, spaced at least 1-day apart. At each overnight visit, participants will complete anthropometric measures and psychometric questionnaires, and memory and attention tasks 30 minutes before and after an 8-hour overnight sleep opportunity. Blood samples will be collected before and after sleep to measure changes in levels of dementia biomarkers. Functional near-infrared spectroscopy will be used to measure overnight brain oxygen and blood flow. Participants will be fitted with a 256 channel high-density electroencephalography (EEG) sensor net cap with the stimulation electrodes nested between the EEG sensors on the cap. Stimulation will be delivered using the Soterix M×N 33/65 High Definition-transcranial Electrical Stimulator using sintered HD electrodes. Active stimulation will consist of an anodal current sinusoidally oscillating at a frequency of 0.75 Hz between zero and 260 µA. The maximum current density will be 0.522 mA/cm2. Channel impedance will be less than 2 kOhms. The low level so-tDCS stimulation will be applied in 5 x 5-minute stimulation blocks by a trained researcher. Participants will be monitored for at least 9 hours following each stimulation while they are asleep and in the morning after they wake up.
Stimulation will be delivered by a researcher 4 minutes from the first onset of stable non-rapid eye movement (NREM) (N2 or N3) period. Participant’s sleep EEG will be continuously monitored and visual confirmation of NREM sleep is required before stimulation is applied. If a participant falls out of stable NREM sleep into N1 sleep, wake or REM sleep during the stimulation free period, stimulation will be paused until stable NREM sleep resumes for a period of 2 minutes.
Intervention code [1] 334002 0
Treatment: Devices
Description of the comparator or control
The sham condition will be identical to the stimulation conditions however the stimulation intensity will not be high enough to generate meaningful cortical excitability (<0.1mA). Sham stimulation will be delivered during an overnight visit at the Woolcock Institute of Medical Research using the Soterix M×N 33/65 High Definition-transcranial Electrical Stimulator using sintered HD electrodes by a trained researcher. Participants will be monitored for at least 9 hours following the sham stimulation while they are asleep and in the morning after they wake up.
Control group
Placebo

Outcomes
Primary outcome [1] 345352 0
Low-delta electroencephalography (EEG) power
Timepoint [1] 345352 0
Data is assessed on the first and only night per treatment.
Secondary outcome [1] 461362 0
Delta electroencephalography (EEG) power
Timepoint [1] 461362 0
The outcome will be assessed at all study visits. EEG will be measured after each stimulation block on the first and only night per treatment.
Secondary outcome [2] 461363 0
Electroencephalography (EEG) power (1-45 Hz frequency band) at 1 Hz frequency bin
Timepoint [2] 461363 0
Data is assessed on the first and only night per treatment.
Secondary outcome [3] 461364 0
Image recognition accuracy
Timepoint [3] 461364 0
Data is assessed before and after the first and only night per treatment.
Secondary outcome [4] 461365 0
Location recognition accuracy
Timepoint [4] 461365 0
Data is assessed before and after the first and only night per treatment.
Secondary outcome [5] 461366 0
Word pairs cued-recall performance accuracy
Timepoint [5] 461366 0
Data is assessed before and after the first and only night per treatment.
Secondary outcome [6] 461367 0
Psychomotor vigilance task - mean reciprocal reaction time (RT)
Timepoint [6] 461367 0
Data is assessed before and after the first and only night per treatment.
Secondary outcome [7] 461368 0
Slow oscillation density (Tertiary outcome)
Timepoint [7] 461368 0
Data is assessed on the first and only night per treatment.
Secondary outcome [8] 461369 0
Slow oscillation peak-to-peak amplitude (Tertiary outcome)
Timepoint [8] 461369 0
Data is assessed on the first and only night per treatment.
Secondary outcome [9] 461370 0
Spindle density (Tertiary outcome)
Timepoint [9] 461370 0
Data is assessed on the first and only night per treatment.
Secondary outcome [10] 461371 0
Slow oscillation (SO)-spindle coupling density (Tertiary outcome)
Timepoint [10] 461371 0
Data is assessed on the first and only night per treatment.
Secondary outcome [11] 461372 0
Slow oscillation (SO)-spindle coupling phase (Tertiary outcome)
Timepoint [11] 461372 0
Data is assessed on the first and only night per treatment.
Secondary outcome [12] 461373 0
Slow oscillation (SO)-spindle coupling strength (Tertiary outcome)
Timepoint [12] 461373 0
Data is assessed on the first and only night per treatment.
Secondary outcome [13] 461374 0
Slow wave and cerebral blood flow (CBF) oscillations coupling density (Tertiary outcome)
Timepoint [13] 461374 0
Data is assessed on the first and only night per treatment.
Secondary outcome [14] 461375 0
Blood levels of Aß (Tertiary outcome)
Timepoint [14] 461375 0
Data is assessed before and after the first and only night per treatment.
Secondary outcome [15] 461376 0
Blood levels of p-tau 217 (Tertiary outcome)
Timepoint [15] 461376 0
Data is assessed before and after the first and only night per treatment.
Secondary outcome [16] 461377 0
Sleep respiratory events (Safety outcome)
Timepoint [16] 461377 0
Data is assessed on the first and only night per treatment.
Secondary outcome [17] 461378 0
Sleep macro-architecture – sleep stages (Tertiary outcome)
Timepoint [17] 461378 0
Data is assessed on the first and only night per treatment.
Secondary outcome [18] 461379 0
Sleep macro-architecture – wake after sleep onset (Tertiary outcome)
Timepoint [18] 461379 0
Data is assessed on the first and only night per treatment.
Secondary outcome [19] 461380 0
.Sleep macro-architecture – arousal index (Tertiary outcome)
Timepoint [19] 461380 0
Data is assessed on the first and only night per treatment.
Secondary outcome [20] 461381 0
Low-delta electroencephalography (EEG) power during post-stimulation period (Tertiary outcome)
Timepoint [20] 461381 0
Data is assessed on the first and only night per treatment.
Secondary outcome [21] 461382 0
Delta electroencephalography (EEG) power during post-stimulation period (Tertiary outcome)
Timepoint [21] 461382 0
Data is assessed on the first and only night per treatment.
Secondary outcome [22] 464307 0
Word pairs performance - morning recognition score (Tertiary outcome)
Timepoint [22] 464307 0
Data is assessed after the first and only night per treatment.

Eligibility
Key inclusion criteria
Participants will be included if they
- Are aged 40 to 75 years of age;
- Have mild to severe obstructive sleep apnoea (OSA) (apnoea hypopnea index (AHI) greater than or equal to 5 events/hour on polysomnography (PSG) / or 3% oxygen desaturation index > 10 events/hour), and stable non-rapid eye movement (NREM) sleep;
- Are fluent in English;
- Are able to perform cognitive tasks;
- Are willing to provide informed consent;
- Are willing to participate and comply with the study requirements.
Minimum age
40 Years
Maximum age
75 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Participants will be excluded if they
- Have a history of head injury with associated loss of consciousness >30 minutes;
- Have any current or previous diagnosis of psychiatric conditions (other than well managed affective disorders – Patient Health Questionnaire-9 <15 severity and no current feelings of suicidality as determined by item 9, Generalised Anxiety Disorder-7 4 standard drinks on any one day);
- Are a current shift-worker or travel overseas within the last 2 weeks;
- Have previously used treatment for obstructive sleep apnea (e.g. CPAP) in the last month;
- Are currently pregnant;
- Have a history of migraine;
- Have metallic implants including intracranial electrodes, surgical clips, shrapnel or a pacemaker;
- Have history of seizure;
- Have had adverse effects to previous brain stimulation methods;
- Previous adverse reaction to topical anaesthetic;
- Have a diagnosis of another primary sleep disorder (determined via medical screening or Insomnia Severity Index question 1 score greater than or equal 10).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is concealed. A random sequence of intervention order will be generated on a computer by an independent researcher not involved in participant recruitment. The intervention will only be revealed to the researchers conducting the intervention after enrolment.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by an independent investigator using computer software
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Low-delta EEG power, delta EEG power, slow oscillation density, slow oscillation peak-to-peak amplitude, spindle density, slow oscillation-spindle coupling density, slow oscillation-spindle coupling phase, slow oscillation-spindle coupling strength and slow wave-cerebral blood flow oscillations coupling density will be the dependent variables calculated for each stimulation block. A mixed effects linear model will be fitted to the data of each EEG channel, including a fixed effect of condition (three levels) and a random intercept for each participant and randomised treatment order. To correct for multiple comparisons across EEG channels, we will apply statistical non-parametric mapping (SnPM) cluster analysis using a cluster-defining threshold of alpha<0.05 with 10000 permutations. When count variables are not sufficiently linear, we will fit a Poisson model to the data.

EEG power between 1 to 45Hz frequency band (at 1Hz resolution) will be the dependent variable calculated for each stimulation block and will be averaged across channels in the pre-defined region of interests. A mixed effects linear model will be fitted to the data of each EEG channel in the pre-defined region of interests, including a fixed effect of condition (three levels) and a random intercept for each participant and randomized treatment order, and data will be corrected for multiple comparisons.

Low-delta and delta EEG power during post-stimulation period will be calculated regionally at every electrode and compared across all three conditions. Data will be analysed using a mixed effects linear model fitted to the data of each EEG channel, including a fixed effect of condition (three levels) and a random intercept for each participant and randomised treatment order, and data will be corrected for multiple comparisons using a threshold of alpha<0.05. To correct for multiple comparisons across EEG channels, we will apply statistical non-parametric mapping (SnPM) cluster analysis using a cluster-defining threshold of alpha<0.05 with 10000 permutations.

Blood levels of Aß and p-tau, sleep respiratory events, sleep macro-architecture events including sleep stages, wake after sleep onset and arousal index, and behavioural outcomes including picture recognition accuracy, location recognition accuracy, word pairs cued-recall performance accuracy, and psychomotor vigilance task outcome will be compared across all three conditions and analysed using a mixed effects linear model, including a fixed effect of condition (three levels) and a random intercept for each participant and randomised treatment order.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 29494 0
Woolcock Institute of Medical Research - Glebe
Recruitment postcode(s) [1] 45811 0
2113 - Macquarie Park

Funding & Sponsors
Funding source category [1] 321809 0
Government body
Name [1] 321809 0
National Health and Medical Research Council (NHMRC) 2021 Investigator Grants Emerging Leadership 2 (EL2) GNT2008001
Country [1] 321809 0
Australia
Primary sponsor type
Government body
Name
National Health and Medical Research Council (NHMRC) 2021 Investigator Grants Emerging Leadership 2 (EL2) GNT2008001
Address
Country
Australia
Secondary sponsor category [1] 324660 0
None
Name [1] 324660 0
Address [1] 324660 0
Country [1] 324660 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320354 0
Macquarie University Human Research Ethics Committee Medical Sciences
Ethics committee address [1] 320354 0
Ethics committee country [1] 320354 0
Australia
Date submitted for ethics approval [1] 320354 0
18/08/2025
Approval date [1] 320354 0
11/11/2025
Ethics approval number [1] 320354 0
520251955765194

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150194 0
A/Prof Angela D’Rozario
Address 150194 0
Woolcock Institute of Medical Research, 2 Innovation Rd, Macquarie Park NSW 2113
Country 150194 0
Australia
Phone 150194 0
+61 02 9805 3246
Fax 150194 0
Email 150194 0
Contact person for public queries
Name 150195 0
Miss Josephine Tang
Address 150195 0
Woolcock Institute of Medical Research, 2 Innovation Rd, Macquarie Park NSW 2113
Country 150195 0
Australia
Phone 150195 0
+61 02 9805 3254
Fax 150195 0
Email 150195 0
Contact person for scientific queries
Name 150196 0
Miss Josephine Tang
Address 150196 0
Woolcock Institute of Medical Research, 2 Innovation Rd, Macquarie Park NSW 2113
Country 150196 0
Australia
Phone 150196 0
+61 02 9805 3254
Fax 150196 0
Email 150196 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
• Published results
• Primary outcome(s)
• Safety data
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Studies exploring new research questions
• Teaching research methods or developing new statistical techniques
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.